Tesofensine (NS2330) Query Orthography and Triple Monoamine Reuptake Pharmacology: A Research Review of Phenyltropane Mechanism, TIPO Clinical Programme and Catalogue Vocabulary

By the Peptide Insider Research Desk · 10 min read

Search queries such as "what is tesofensine used for", "is tesofensine a peptide", "tesofensine buy", "tesofensine cost" and the common misspelling "tesofensive" collectively account for substantial monthly search traffic in the research-compound space. A related cluster — "buy tesofensine online", "tesofensine where to buy", "tesofensine peptide buy", "tesofensine peptide for sale", "tesofensine purchase" and "tesofensine amazon" — reflects the growing catalogue interest in this investigational monoamine reuptake inhibitor. Marketplace labels including "tesofensine price", "tesofensine prescription", "tesofensine supplement", "tesofensine 250mcg", "tesofensine bodybuilding" and the phonetic variant "tesofine" further demonstrate the breadth of vocabulary that researchers encounter. Additional catalogue entries such as "racemic tesofensine" and "tesofensine dosing" reference stereochemical and protocol dimensions that fall outside the scope of this research-use-only review. This article surveys the published preclinical and clinical literature on tesofensine (NS2330, CAS 195875-84-4) to provide a referenced framework for investigators evaluating this compound class.

Mechanism of Action: Triple Monoamine Reuptake Inhibition

Tesofensine inhibits the synaptic reuptake of norepinephrine (NE), serotonin (5-HT) and dopamine (DA) by blocking their respective plasma-membrane transporters — the norepinephrine transporter (NET), serotonin transporter (SERT) and dopamine transporter (DAT). Reported in vitro IC₅₀ values are 1.7 nM (NET), 11 nM (SERT) and 65 nM (DAT), indicating preferential NET affinity followed by SERT and DAT [1][3]. The resulting elevation of monoamine concentrations in the synaptic cleft produces downstream effects on feeding-circuit neurotransmission.

Receptor-antagonism studies in diet-induced obese (DIO) rat models have demonstrated that the hypophagic (appetite-suppressing) activity of tesofensine depends on indirect stimulation of alpha-1 (α₁) adrenoceptors and dopamine D1 receptors. Co-administration of prazosin (α₁ antagonist) or SCH23390 (D1 antagonist) significantly attenuated the compound's effect on food intake, whereas antagonists targeting α₂, D2, D3 and 5-HT_2A/C receptors did not [3]. These findings localise the anorexigenic signal to the NE/α₁ and DA/D1 arms of the triple-reuptake cascade.

Positron-emission tomography (PET) imaging in human subjects has confirmed dose-dependent DAT occupancy in the striatum following chronic tesofensine administration. A reduction in striatal D2/D3 receptor availability was also observed — interpreted as an adaptive consequence of sustained dopaminergic tone rather than as the primary effector of intake reduction [4][5].

Pharmacokinetics and Metabolism

Tesofensine displays a notably long elimination half-life of approximately 220 hours (~9 days) in humans, supporting once-daily oral administration. The compound is primarily metabolised by hepatic cytochrome P450 3A4 (CYP3A4) into a single detectable plasma metabolite, desalkyl-tesofensine (NS2360, M1), which possesses an even longer half-life of approximately 374 hours (~16 days) [1][6]. NS2360 is pharmacologically active but contributes an estimated 6% of the total pharmacological effect of the parent compound [6].

Population pharmacokinetic modelling in Alzheimer's disease patients established a one-compartment model for both tesofensine and M1, with oral clearance estimated at 30–40 mL/min and renal excretion accounting for approximately 15–20% of total elimination [6]. Because tesofensine is a CYP3A4 substrate, co-administration with strong CYP3A4 inhibitors (e.g., itraconazole) has been shown via semi-mechanistic modelling to reduce clearance and increase systemic exposure [7].

Preclinical Evidence

Clinical Literature: The TIPO Programme

The pivotal clinical data set for tesofensine derives from the TIPO (Tesofensine In the treatment of Patients with Obesity) programme, conducted in Denmark under the sponsorship of NeuroSearch A/S.

TIPO-1 (Phase IIB; NCT00394667). Astrup et al. (2008) enrolled 203 obese participants (BMI 30–40 kg/m²) in a 24-week, randomised, double-blind, placebo-controlled trial evaluating three oral doses (0.25 mg, 0.5 mg, 1.0 mg) against placebo. All groups received mild dietary counselling (−300 kcal/day) and an instruction to increase physical activity. Placebo-subtracted mean weight loss was 4.5% (0.25 mg), 9.2% (0.5 mg) and 10.6% (1.0 mg). The compound preferentially reduced fat mass while preserving lean mass. Common adverse events included dry mouth, insomnia, nausea and constipation; dose-dependent heart-rate increases of 7–9 bpm were noted in the higher-dose arms [8].

TIPO-4 (Extension). A 48-week open-label extension corroborated the sustained trajectory, with cumulative weight reductions reaching 13–14 kg in some cohorts [1][9]. The cardiovascular signal — modest increases in heart rate and blood pressure (1–3 mmHg) — prompted a companion hypertensive-management sub-study (Siebenhofer et al., 2013) that demonstrated the co-administration of standard anti-hypertensive agents preserved the appetite-suppressing effect of tesofensine while mitigating cardiovascular elevations [10].

Neurodegenerative-Disease Heritage

Before its repositioning toward metabolic research, tesofensine (as NS2330) was evaluated in two neurodegenerative indications. A 14-week Phase II proof-of-concept study in patients with mild-to-moderate Alzheimer's disease generated the foundational population-pharmacokinetic model [6]. A separate trial in advanced Parkinson's disease with motor fluctuations (Rascol et al., 2008) examined whether triple monoamine reuptake inhibition could ameliorate on/off cycling [11]. Neither programme advanced to Phase III for its original indication; however, the incidental observation of significant weight loss during Phase I and II studies catalysed the pivot to metabolic research [1][11].

Query Orthography and Catalogue Vocabulary Crosswalk

Is Tesofensine a Peptide?

The query "is tesofensine a peptide" appears frequently in research-compound catalogues that co-list peptides alongside small molecules. Tesofensine is not a peptide. It is a low-molecular-weight synthetic phenyltropane (MW 328.28 g/mol) — a tropane-ring bicyclic structure bearing a 3,4-dichlorophenyl substituent and an ethoxymethyl side chain. Peptides, by contrast, are oligomers of amino-acid residues linked by amide bonds, typically ranging from ~200 Da (dipeptide) to several thousand daltons. Tesofensine contains no amino-acid residues and no peptide bonds. Its inclusion in peptide-oriented catalogues is a commercial artefact of vendor inventory scope, not a reflection of structural or biosynthetic classification [1].

Frequently Asked Questions

What is tesofensine used for in research?

Tesofensine (NS2330) is an investigational triple monoamine reuptake inhibitor studied in preclinical and clinical research for its effects on monoaminergic neurotransmission and energy-balance pathways. It was originally evaluated in Alzheimer's and Parkinson's disease trials before being redirected to metabolic research [1][6][11].

Is tesofensine a peptide?

No. Tesofensine is a synthetic phenyltropane small molecule (MW 328.28 g/mol, CAS 195875-84-4). It contains no amino-acid residues or peptide bonds. Its presence in peptide-oriented catalogues is a vendor-inventory artefact [1].

What is racemic tesofensine?

Racemic tesofensine refers to a non-enantiopure mixture of the (1R,2R,3S) and (1S,2S,3R) enantiomers. The clinical programme (TIPO-1, TIPO-4) studied the defined (1R,2R,3S) single enantiomer. Racemic preparations appear in some catalogue listings but were not part of the pivotal trials [1][8].

What does "tesofensive" or "tesofine" refer to?

"Tesofensive" is a phonetic misspelling and "tesofine" is a truncation misspelling of tesofensine. Both resolve to the same compound: NS2330, CAS 195875-84-4.

Where can researchers source tesofensine for laboratory use?

Research-grade tesofensine may be obtained from specialist suppliers such as Short Chain Aminos, BioPep, Catalyst Research and Apex Research Services. Investigators should confirm purity certificates and certificates of analysis (COA) before use.

Where to Source for Research

Tesofensine reference material for preclinical investigation is listed by several specialist compound suppliers. Short Chain Aminos carries a broad catalogue of research-grade small molecules and peptides and serves as a primary reference source. Additional suppliers include BioPep, Catalyst Research and Apex Research Services. No individual vendor is assessed or endorsed by this publication; investigators are responsible for verifying certificates of analysis, enantiomeric purity and regulatory compliance in their jurisdiction.

Works Cited

1. Wikipedia contributors. "Tesofensine." Wikipedia, The Free Encyclopedia. Accessed 9 Oct 2026. https://en.wikipedia.org/wiki/Tesofensine
2. Cheung BM, Cheung TT, Samaranayake NR. Safety of antiobesity drugs. Ther Adv Drug Saf. 2013;4(4):171-181. PMID: 25114779
3. Hansen HH, Hansen G, Tang-Christensen M, et al. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology. 2010;35(7):1464-1476. PMID: 20200509
4. Appel L, Bergström M, Gee AD, et al. Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET. Eur Neuropsychopharmacol. 2014;24(2):251-261. PMID: 24239329
5. Hansen HH, Hansen G, Paulsen S, et al. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur Neuropsychopharmacol. 2012;22(5):362-372. PMID: 21889317
6. Lehr T, Staab A, Tillmann C, et al. Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. Br J Clin Pharmacol. 2007;64(1):36-48. PMID: 17324246
7. Lehr T, Staab A, Tillmann C, et al. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole. Clin Pharmacokinet. 2010;49(1):53-66. PMID: 20000889
8. Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906-1913. PMID: 18950853
9. Doggrell SA. Tesofensine — a novel potent weight loss medicine. Expert Opin Investig Drugs. 2009;18(7):1043-1046. PMID: 19548858
10. Siebenhofer A, Glechner A, Gall H, et al. Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in obese hypertensive rats. Obesity (Silver Spring). 2013;21(11):2236-2243. PMID: 23784901
11. Rascol O, Poewe W, Lees A, et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations. Arch Neurol. 2008;65(5):577-583. PMID: 18474731

This article is provided strictly for research reference; it is not intended as, and must not be construed as, guidance for human or veterinary use. Tesofensine is an investigational compound that has not received regulatory approval for any indication. No vendor mentioned herein is assessed or endorsed by this publication.